Making Treatment Decisions About Discontinuing TKIs in Chronic Myeloid Leukemia
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
Leukemia
LEUKEMIA
FEATURE
LATEST ARTICLES
Idelalisib-Rituximab Combo Found Active in R/R CLL Regardless of Complex Karyotype
Presence of a complex karyotype did not affect progression-free or overall survival.
Incidence of GI Adverse Events Associated With CAR-T Therapy for Lymphoma or Leukemia Is Low
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
Treatment Delays With CAR-T Therapy: A High Price to Pay
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Venetoclax Plus Hypomethylating Agents May Offer Treatment Backbone for High-Risk AML
Over half of patients with TP53-mutated acute myeloid leukemia who received the combination therapy experienced a response.
Maintenance Therapy in Acute Myeloid Leukemia: An Overview
In a review article, researchers discussed maintenance treatment strategies using chemotherapy, immunotherapy, targeted small molecules, and more.
Outcomes With Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Nilotinib was associated with high adherence to treatment and fairly high quality of life, and nearly all evaluated patients achieved a major molecular response.
Familial Risks Associated With Hematologic Malignancies
Certain malignancies, younger age at diagnosis, and multiple affected relatives were all associated with increased familial relative risks.
Use of MRD Status Following Obinutuzumab/Ibrutinib to Guide Subsequent Therapy Selection in CLL
This trial employed chemotherapy-free induction therapy followed by assessment of MRD status to triage patients for subsequent therapy with or without chemotherapy.
HLA-B27 Positivity Did Not Influence CLL, SLL Outcomes
Further studies needed to look at relevance outside of the transplant-eligible population.
After Long-Term Ibrutinib Therapy for CLL, BTK Mutations May Signal Progression
Some patients with BTK mutations could benefit from treatment changes at earlier stages.
A Tool to Select Candidates for Allogeneic Hematopoietic Cell Transplant in CLL
As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.
Umbilical Cord Blood Transplantation in Adolescents and Young Adults With Acute Leukemia
At 3 years, the rates of overall and leukemia-free survival were 45% and 41%, respectively.
Low ADAMTS13 Activity Associated With Poor Prognosis in Acute Myeloid Leukemia
Patients with ADAMTS13 activity below a cutoff of 481 ng/mL had more bone marrow transplant-related complications, according to researchers.
Improved Survival Outcomes With Ibrutinib Plus Rituximab in Chronic Lymphocytic Leukemia
Patients who received ibrutinib and rituximab had a 3-year PFS rate of 89.4%, compared with 72.9% in patients receiving chemoimmunotherapy.
Do Oncologists Change Practice Based on Inadequate Evidence?
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Sorafenib Plus Intensive Chemotherapy Improves Outcomes in FLT3-Mutated Acute Myeloid Leukemia
Median overall survival was 42 months in patients who received sorafenib and 13 months in patients who received chemotherapy alone.
Intensification With Myeloid-Type Chemotherapy May Not Improve Outcomes in Infants With ALL
Type of chemotherapy did not result in significant differences in disease-free or overall survival.
FDA Greenlights New Rituxan Biosimilar
The Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan (Genentech and Biogen), for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangitis and microscopic polyangiitis. The approval was based on a comprehensive data package which included results from the REFLECTIONS B3281006 study in…
Prognostic Model for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Researchers sought to develop a model that can be used to identify patients receiving targeted therapy for CLL who are at high risk for poor outcomes.
Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL
Inferior survival for patients with chronic lymphocytic leukemia who progress with lymphadenopathy
Does Preemptive Stem Cell Transplant Have Value for Patients at Genetic Risk for Leukemia?
Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.
Flow Cytometry as a Relapse Risk Assessment Tool in T-Cell Acute Lymphoblastic Leukemia
An alternative measure of relapse risk is needed in patients for whom no polymerase chain reaction marker is available.
Predicting Bleeding Risk in Acute Myeloid Leukemia With Thrombocytopenia With Platelet Function Tests
Platelet aggregation and platelet activation were both independently associated with bleeding risk.
Efficacy of Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia
The majority of patients achieved complete remission with or without incomplete count recovery after receiving 12 cycles of combination therapy.
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
Greater Infection Risk With Unrelated Transplant Donors in Pediatric Acute Lymphoblastic Leukemia
The increased risk for infection seen in pediatric patients receiving transplants from unrelated donors could be a result of intensified graft-versus-host disease prophylaxis.
Identifying Risk Factors for Second Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia
Rates of leukemia-free and overall survival were 20% and 30%, respectively, at 2 years and 12% and 14%, respectively, at 5 years.
Study Found Gilteritinib Superior to Salvage Chemotherapy in FLT3-Mutated Refractory AML
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
Low Response Rates to Hypomethylating Agents in Chronic Myelomonocytic Leukemia
Researchers evaluated response rates to azacitidine and decitabine in patients with chronic myelomonocytic leukemia according to various sets of response criteria.
Novel Postremission Therapeutic Agents for Patients With Acute Myeloid Leukemia
Results from ongoing trials suggest targeted therapy may improve survival outcomes in acute myeloid leukemia, but further research is needed.
Efficacy of Bosutinib in Chronic Myeloid Leukemia Resistant to Prior Treatment
A substantial proportion of patients who received bosutinib achieved major cytogenetic response and molecular response within 1 year.
Induction Chemotherapy Intensity May Not Influence Survival in Acute Myeloid Leukemia
Intensity of induction chemotherapy was associated with measurable residual disease negativity but not overall survival.
Long-Term Outcomes of Ibrutinib in Chronic Lymphocytic Leukemia
Patients receiving ibrutinib had an overall response rate of 8% and median progression-free survival of 44.1 months.
Treatment-Free Remission After Nilotinib May Be Durable in Chronic Myeloid Leukemia
Among 126 patients who entered treatment-free remission, 58 remained in remission at 192 weeks.
The Influence of Smoking Status on Survival and Relapse in Acute Myeloid Leukemia
Researchers sought to expand upon what is known about smoking status and AML diagnosis and understand more about how smoking affects treatment outcomes.
Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia
A significantly greater proportion of patients in the flumatinib group had a complete molecular response at 12 months compared with in the imatinib group.
Rates of Transcript Variants in Chronic Myeloid Leukemia Associated With Sex and Age
The e13a2 transcript was expressed more frequently in men and pediatric patients.
Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Muscle Complaints Are a Frequent Side Effect of TKI Use in CML, but What Causes Them?
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Navigating Cancer Communication on Twitter
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Clinical Outcomes in Philadelphia-Negative ALL With Inotuzumab Ozogamicin Plus Chemotherapy
Propensity score analysis showed that patients in the inotuzumab ozogamicin arm experienced significantly longer event-free and overall survival.
The Cost of Cancer Treatment: Financial Toxicity in Acute Leukemia
What is the role of the clinician in managing financial toxicity?
A Changing Landscape: The Future of Treatment for Acute Myeloid Leukemia
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
Tumor Lysis Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax
High risk for tumor lysis syndrome and creatinine clearance below 80 mL/min were associated with tumor lysis syndrome development.
Tibsovo Approved to Treat Newly Diagnosed AML With IDH1 Mutation
The FDA has expanded the indication for Tibsovo to include treatment of newly diagnosed acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
“Another CAR in the Garage”: Q&A on CAR-T With UPenn’s Bruce Levine, PhD
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
Increased Incidence of Second Malignancies in Patients With Chronic Myeloid Leukemia
Researchers assessed 13,276 patients with chronic myeloid leukemia to characterize the incidence and types of second malignancies in this patient population.
Conditioning Chemotherapy Preceding CAR T-Cell Therapy Appears to Be Safe in Relapsed/Refractory CLL
Patients enrolled in a phase 1 trial receiving ibrutinib demonstrated augmented ex vivo CAR T-cell expansion.
Leukemia: What Your Patients Need to Know
Your patients may have questions about leukemia. Help them better understand the condition by sharing this article with them.
Want to read more?
Please login or register first to view this content.
Next post in Leukemia
